Importer of Controlled Substances; Notice of Application, 27347 [E9-13353]
Download as PDF
<![CDATA[
27347
Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices
FOR FURTHER INFORMATION CONTACT:
Patrick W. McDonough, Executive
Director of the Joint Board for the
Enrollment of Actuaries, 202–622–8225.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Advisory
Committee on Actuarial Examinations
will meet in the Internal Revenue
Service Building, 1111 Constitution
Avenue, NW., Washington, DC on
Monday, June 29, 2009, from 9 a.m. to
5 p.m., and Tuesday, June 30, 2009,
from 8:30 a.m. to 5 p.m.
The purpose of the meeting is to
discuss topics and questions which may
be recommended for inclusion on future
Joint Board examinations in actuarial
mathematics and methodology referred
to in 29 U.S.C. 1242(a)(1)(B) and to
review the May 2009 Basic (EA–1) and
Pension (EA–2B) Joint Board
Examinations in order to make
recommendations relative thereto,
including the minimum acceptable pass
score. Topics for inclusion on the
syllabus for the Joint Board’s
examination program for the November
2009 Pension (EA–2A) Examination will
be discussed.
A determination has been made as
required by section 10(d) of the Federal
Advisory Committee Act, 5 U.S.C. App.,
that the portions of the meeting dealing
with the discussion of questions that
may appear on the Joint Board’s
examinations and the review of the May
2009 Joint Board examinations fall
within the exceptions to the open
meeting requirement set forth in 5
U.S.C. 552b(c)(9)(B), and that the public
interest requires that such portions be
closed to public participation.
The portion of the meeting dealing
with the discussion of the other topics
will commence at 1 p.m. on June 29 and
will continue for as long as necessary to
complete the discussion, but not beyond
3 p.m. Time permitting, after the close
of this discussion by Committee
members, interested persons may make
statements germane to this subject.
Persons wishing to make oral statements
must notify the Executive Director in
writing prior to the meeting in order to
aid in scheduling the time available and
must submit the written text, or at a
minimum, an outline of comments they
propose to make orally. Such comments
will be limited to 10 minutes in length.
All other persons planning to attend the
public session must also notify the
Executive Director in writing to obtain
building entry. Notifications of intent to
make an oral statement or to attend
must be faxed, no later than June 19,
2009, to 202–622–8300, Attn: Executive
Director. Any interested person also
may file a written statement for
VerDate Nov<24>2008
16:42 Jun 08, 2009
Jkt 217001
consideration by the Joint Board and the
Committee by sending it to the
Executive Director: Joint Board for the
Enrollment of Actuaries, c/o Internal
Revenue Service, Attn: Executive
Director SE:OPR, Room 7238, 1111
Constitution Avenue, NW., Washington,
DC 20224.
Dated: May 26, 2009.
Patrick W. McDonough,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. E9–13517 Filed 6–8–09; 8:45 am]
BILLING CODE 4830–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
This is notice that on January 28,
2009, Stepan Company, Natural
Products Department, 100 W. Hunter
Avenue, Maywood, New Jersey 07607,
made application by renewal to the
Drug Enforcement Administration
(DEA) for registration as an importer of
Coca Leaves (9040), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance for the
manufacture of a bulk controlled
substance for distribution to its
customer.
No comments, objections, or requests
for any hearings will be accepted on any
application for registration or reregistration to import coca leaves. As
explained in the Correction to Notice of
Application pertaining to Rhodes
Technologies, 72 FR 3417 (2007),
comments and requests for hearings on
applications to import narcotic raw
material are not appropriate.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
Springfield, VA 22152; and must be
filed no later than July 9, 2009.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–13353 Filed 6–8–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on March
18, 2009, Research Triangle Institute,
Kenneth H. Davis Jr., Hermann
Building, East Institute Drive, P.O. Box
12194, Research Triangle, North
Carolina 27709, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
1-(1-Phenylcyclohexyl)pyrrolidine
(7458).
1-[1-(2-Thienyl)cyclohexy]piperidine (7470).
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473).
E:\FR\FM\09JNN1.SGM
09JNN1
Schedule
I
I
I
]]>Agencies
[Federal Register Volume 74, Number 109 (Tuesday, June 9, 2009)]
[Notices]
[Page 27347]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-13353]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
This is notice that on January 28, 2009, Stepan Company, Natural
Products Department, 100 W. Hunter Avenue, Maywood, New Jersey 07607,
made application by renewal to the Drug Enforcement Administration
(DEA) for registration as an importer of Coca Leaves (9040), a basic
class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for the
manufacture of a bulk controlled substance for distribution to its
customer.
No comments, objections, or requests for any hearings will be
accepted on any application for registration or re-registration to
import coca leaves. As explained in the Correction to Notice of
Application pertaining to Rhodes Technologies, 72 FR 3417 (2007),
comments and requests for hearings on applications to import narcotic
raw material are not appropriate.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedule I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR
1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, VA 22152; and must be filed no later
than July 9, 2009.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e), and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975 (40 FR 43745), all applicants for
registration to import a basic class of any controlled substances in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: June 3, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-13353 Filed 6-8-09; 8:45 am]
BILLING CODE 4410-09-P
